VU0155041

Last updated

VU0155041
VU0155041.svg
Identifiers
  • (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C14H15Cl2NO3
Molar mass 316.18 g·mol−1
3D model (JSmol)
  • C1CC[C@H]([C@H](C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)C(=O)O
  • InChI=1S/C14H15Cl2NO3/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20)/t11-,12+/m0/s1
  • Key:VSMUYYFJVFSVCA-NWDGAFQWSA-N

VU0155041 is an experimental drug that is a positive allosteric modulator for the glutamate receptor mGluR4. In animal studies it has anti-Parkinsonian action, reduces neuropathic pain such as allodynia, and counteracts the effects of opioid addiction. [1] [2] [3] [4] [5] [6] [7] [8] [9]

References

  1. ↑ Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, et al. (November 2008). "Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4". Molecular Pharmacology. 74 (5): 1345–1358. doi:10.1124/mol.108.049551. PMC   2574552 . PMID   18664603.
  2. ↑ Williams R, Johnson KA, Gentry PR, Niswender CM, Weaver CD, Conn PJ, et al. (September 2009). "Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4)". Bioorganic & Medicinal Chemistry Letters. 19 (17): 4967–4970. doi:10.1016/j.bmcl.2009.07.072. PMC   2752865 . PMID   19640716.
  3. ↑ Wang H, Jiang W, Yang R, Li Y (March 2011). "Spinal metabotropic glutamate receptor 4 is involved in neuropathic pain". NeuroReport. 22 (5): 244–248. doi:10.1097/WNR.0b013e3283453843. PMID   21358553.
  4. ↑ Betts MJ, O'Neill MJ, Duty S (August 2012). "Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease". British Journal of Pharmacology. 166 (8): 2317–2330. doi:10.1111/j.1476-5381.2012.01943.x. PMC   3448896 . PMID   22404342.
  5. ↑ Becker JA, Clesse D, Spiegelhalter C, Schwab Y, Le Merrer J, Kieffer BL (August 2014). "Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity". Neuropsychopharmacology. 39 (9): 2049–2060. doi:10.1038/npp.2014.59. PMC   4104328 . PMID   24619243.
  6. ↑ Ebrahimi Z, Kahvandi N, Komaki A, Karimi SA, Naderishahab M, Sarihi A (March 2021). "The role of mGlu4 receptors within the nucleus accumbens in acquisition and expression of morphine-induced conditioned place preference in male rats". BMC Neuroscience. 22 (1): 17. doi: 10.1186/s12868-021-00627-2 . PMC   7981834 . PMID   33743609.
  7. ↑ Becker JA, Pellissier LP, Corde Y, Laboute T, Léauté A, Gandía J, et al. (June 2021). "Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice". Neuropsychopharmacology. 46 (7): 1373–1385. doi:10.1038/s41386-020-00927-x. PMC   8136479 . PMID   33349673.
  8. ↑ Ebrahimi Z, Kahvandi N, Shahriari E, Komaki A, Karimi SA, Naderishahab M, et al. (June 2023). "VU0155041, a positive allosteric modulator of mGluR4, in the nucleus accumbens facilitates extinction and inhibits the reinstatement of morphine-induced conditioned place preference in male rats". Brain Research Bulletin. 197: 57–64. doi: 10.1016/j.brainresbull.2023.03.012 . PMID   36997034.
  9. ↑ Xu YL, Xia YT, Zhang MM, Li YJ, Tao XX, Li K, et al. (June 2025). "Red nucleus mGluR4 and mGluR8 inhibit nociception and the development of neuropathic pain by restraining the expressions of TNF-α and IL-1β". Neuropharmacology. 271 110387. doi: 10.1016/j.neuropharm.2025.110387 . PMID   40010564.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.